| Literature DB >> 32548326 |
Alberto Aragón-Muriel1, Yamil Liscano-Martínez2, Ernesto Rufino-Felipe3, David Morales-Morales3, Jose Oñate-Garzón4, Dorian Polo-Cerón1.
Abstract
NovelEntities:
Keywords: Antibacterial activity; Benzimidazole; Cancer; Cytotoxicity; Fluorescence; Inorganic chemistry; Lanthanide complexes; Model membranes; Molecular dynamics
Year: 2020 PMID: 32548326 PMCID: PMC7286978 DOI: 10.1016/j.heliyon.2020.e04126
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Synthesis of lanthanide complexes with ligands HL1 and HL2.
IR bands of HL1 and HL2 ligands and their lanthanide complexes (values in cm−1).
| Compound | υ (N-H) | δ(N-H) | υ(C=N) | υ(C=C) | υ(C-O) | δ(-OH)ip | δ(-OH)op | δ(C-H) |
|---|---|---|---|---|---|---|---|---|
| HL1 | 3500–3300 | 1615 | 1578 | 1509 | 1240 | 1402 | 942 | 754 |
| La-L1 | 3500–3300 | 1618 | 1558 | 1492 | 1262 | - | - | 749 |
| Ce-L1 | 3500–3300 | 1621 | 1555 | 1496 | 1272 | - | - | 752 |
| Sm-L1 | 3500–3300 | 1612 | 1558 | 1496 | 1278 | - | - | 755 |
| HL2 | 3500–3300 | 1638 | 1590 | 1505 | 1253 | 1404 | 944 | 740 |
| La-L2 | 3500–3300 | 1624 | 1548 | 1508 | 1275 | - | - | 742 |
| Ce-L2 | 3500–3300 | 1621 | 1549 | 1505 | 1278 | - | - | 740 |
| Sm-L2 | 3500–3300 | 1624 | 1568 | 1508 | 1278 | - | - | 743 |
ip = in plane.
op = out of plane.
Figure 21H-NMR spectra: (a) superposition of HL1 (red) and La- L1 (blue); (b) comparative 1H-NMR spectrum expansion of (a).
Inhibition of the growth (%) of human tumor cell lines at 25 μM.∗
| Compound | U251 | PC-3 | K562 | HCT-15 | MCF-7 | SKLU-1 | COS-7 |
|---|---|---|---|---|---|---|---|
| HL1 | NA | 19.6 ± 0.7 | 21.6 ± 1.1 | NA | NA | 29.3 ± 1.1 | NA |
| HL2 | NA | NA | NA | NA | NA | NA | NA |
| La-L1 | 1.1 ± 0.9 | 51.3 ± 1.8 | 70.9 ± 2.3 | 15.7 ± 1.0 | 23.3 ± 0.7 | 44.1 ± 0.9 | 13.7 ± 0.5 |
| Ce-L1 | 59.6 ± 2.1 | 53.3 ± 0.7 | 55.8 ± 0.6 | 23.2 ± 0.9 | 30.9 ± 1.2 | 37.0 ± 0.8 | 10.4 ± 0.4 |
| Sm-L1 | 30.3 ± 1.3 | 47.7 ± 1.6 | 56.3 ± 1.5 | 42.8 ± 1.2 | 18.7 ± 0.5 | 47.7 ± 1.1 | 10.4 ± 0.7 |
| La-L2 | NA | 31.5 ± 1.3 | 42.1 ± 2.2 | NA | NA | 27.3 ± 1.6 | NA |
| Ce-L2 | NA | 26.1 ± 0.7 | 34.9 ± 1.4 | NA | NA | 14.3 ± 1.0 | NA |
| Sm-L2 | NA | 17.5 ± 0.5 | 36.5 ± 1.0 | 7.9 ± 1.2 | NA | 13.4 ± 0.7 | NA |
| 90.3 ± 2.0 | 64.8 ± 1.3 | 55.3 ± 2.2 | 50.2 ± 1.4 | 79.9 ± 1.6 | 94.8 ± 2.3 | ND |
The results are the average of three runs. Values are expressed as mean ± SD. NA = Not active, ND = Not determined.
Non-cancerous cell line (primate kidney).
Reference drug.
Figure 3Minimal inhibitory concentrations (MICs) found for the series of compounds in antibacterial assays (μg·mL−1): (a) gram-negative strains; (b) gram-positive strains.
Figure 4Fluorescence studies: (a) the series of compounds dissolved in ethanol, in the absence of light (above), in the presence of normal light (medium) and under ultraviolet light (λ 365 nm) (below); (b) UV-Visible spectra for ligand HL2 and their complexes of La(III), Ce(III) and Sm(III); (c) emission spectra (at λ 343 nm) of ligand HL1 and their complexes; (d) emission spectra (at λ 343 nm) of ligand HL2 and their complexes.
Figure 5Images obtained by fluorescence microscopy on the E. coli: contrast with two microscope filters for E. coli using a solution of compound La-L1 at a concentration of 125 μg·mL−1 (above) and the effect of increasing the concentration of HL1 (below).
Figure 6Absorption spectra of the Sm-1 complex at different concentrations (1.0–5.0 × 10−6 M) in MHB media and the double reciprocal plot of 1/(A−Ao) vs. 1/[Sm-1] (a) at the beginning of the experiment (b) after 24 h of interaction.
Absorption values (A) obtained from lanthanide complexes at different concentrations (λ = 330 or 340 nm) and stability constants in MHB media at the beginning of the experiment and after 24 h.
| Concentration x 10−6 [M] | La-L1 | La-L2 | Ce-L1 | Ce-L2 | Sm-L1 | Sm-L2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 h | 24 h | 0 h | 24 h | 0 h | 24 h | 0 h | 24 h | 0 h | 24 h | 0 h | 24 h | |
| 1.0 | 0.1992 | 0,1980 | 0.4362 | 0.5542 | 0.1526 | 0.1838 | 0.1963 | 0.2141 | 0.1048 | 0.1199 | 0.2562 | 0.2897 |
| 2.0 | 0.3923 | 0,3829 | 0.8409 | 0.9483 | 0.3317 | 0.3634 | 0.3990 | 0.4028 | 0.2166 | 0.2247 | 0.4748 | 0.5517 |
| 3.0 | 0.5995 | 0,5580 | 1.2763 | 1.2763 | 0.4968 | 0.5188 | 0.6075 | 0.5980 | 0.3327 | 0.3390 | 0.7272 | 0.7882 |
| 4.0 | 0.8297 | 0,7394 | 1.5980 | 1.4708 | 0.6993 | 0.6963 | 0.7951 | 0.7930 | 0.4491 | 0.4371 | 0.9871 | 1.0198 |
| 5.0 | 1.0291 | 0,9252 | 1.7367 | 1.6156 | 0.8831 | 0.8487 | 0.9527 | 1.0410 | 0.5583 | 0.5441 | 1.2376 | 1.3005 |
| 8.37 | 8.91 | 9.24 | 9.90 | 4.51 | 4.38 | 2.95 | 3.53 | 3.75 | 3.29 | 3.55 | 3.59 | |
Figure 7DSC thermograms showing peaks of the phase transition of MLVs formed by DMPC/DMPG (3:1) before and after the addition of HL2 (a) and La-L2 (b) at different compound-lipids molar ratios: 0:1 (); 1:50 (); 1:10 ().
Tm and enthalpy transition (DH) values of MLVs constituted by DMPC/DMPG (3:1) before and after the addition of either HL2 and La-L2 at different compound-lipid molar ratios.
| MLV | Compound-lipid molar ratio | Pretransition temperature (°C) | Tm (°C) | DH (J.g−1) |
|---|---|---|---|---|
| DMPC/DMPG (3:1) | 0:1 | 12 | 22.92 | 0.39 |
| DMPC/DMPG (3:1)-HL2 | 1:50 | 23.11 | 0.39 | |
| 1:10 | 22.51 | 0.08 | ||
| DMPC/DMPG (3:1)-La-L2 | 1:50 | 22.85 | 0.22 | |
| 1:10 | 21.95 | 0.11 |
Figure 8RMSD analysis of the HL2 atoms in DMPC-DMPG (a) and E. coli (b) model membranes.
Figure 9Partial density profile in the z direction in the DMPC-DMPG and POPE-POPG membrane systems: (a) represents the DMPC-DMPG model membrane at 0 ns; (b) represents the DMPC-DMPG model membrane at 10 ns; (c) represents the POPE-POPG model membrane at 0 ns; (d) represents the POPE-POPG model membrane at 10 ns.
Figure 10Mechanism of insertion of the ligand into the DMPC-DMPG (a) and POPE-POPG (b) membrane systems. The ligand shown is constituted by the red spheres representing oxygen, blue for nitrogen, white for hydrogen and green for carbon.
Figure 11Number of H-bonds between the two parts of the ligand, namely, the aminophenol region and the benzimidazole region, with DMPC-DMPG (a) and POPE-POPG (b).